CRM upgraded at Sanofi-aventis US

By : |March 15, 2010 0

BEDMINSTER, NEW JERSEY: Sanofi-aventis U.S. is continuing its relationship in the U.S. and will upgrade to Cegedim Dendrite’s flagship CRM product, Mobile Intelligence. Because of multiple changes in the industry, many Life Sciences companies have changed their commercial models in order to adapt to the needs of different types of stakeholders. These companies require a flexible and dynamic CRM system that provides Managed Care, Key Account Management (KAM) and Key Opinion Leader (KOL) configurations to better manage their relationships with these key stakeholders through increased visibility and collaboration, as a press release adds.

Sanofi-aventis U.S. has been leveraging Cegedim Dendrite CRM solutions since 2001. As part of the renewal, sanofi-aventis U.S. will upgrade to Mobile Intelligence, which provides a 360 degree view into customer data, unparalleled flexibility and robust functionality that clearly support the pharmaceutical industry’s evolving commercial model. The upgrade to Mobile Intelligence includes a full suite of supporting services comprised of implementation, data, hardware and help desk services. Various sanofi-aventis U.S. commercial teams will be leveraging different functionality within Mobile Intelligence, depending on the needs of their group and the group’s customers.

“Mobile Intelligence was designed to be flexible, and that flexibility will enable sanofi-aventis U.S. to better support the evolving needs of its stakeholders,” said Mark Fleischer, Senior Vice President and General Manager, North America CRM for Cegedim Dendrite. “We know that customers have a choice in selecting a company to best meet their CRM needs. And that’s why we continue to invest in R&D to develop the highest quality CRM solutions for the Life Sciences industry. This important agreement signals direct feedback about our deep industry understanding and the high value that we deliver to our customers’ operations.”

                                 

___________________________________________________________________________________________________________

 

No Comments so fars

Jump into a conversation

No Comments Yet!

You can be the one to start a conversation.